Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors want to help more people with a type of cancer called multiple myeloma by using a treatment called belantamab mafodotin with lenalidomide. They hope this will make more patients go from having abnormal cells to having healthy cells after a bone marrow transplant.
Doctors want to help more people with a type of cancer called multiple myeloma by using a treatment called belantamab mafodotin with lenalidomide. They hope this will make more patients go from having abnormal cells to having healthy cells after a bone marrow transplant.
*Third Opinion AI Generated Synopsis
Trial Summary
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
